CHE

Over the past six months, Chemed Corp. experienced several stock events. In Q1 2026, Chemed reported earnings per share of $5.65, surpassing estimates, but revenue slightly missed expectations, leading to initial stock volatility. Management raised its full-year 2026 adjusted EPS guidance due to improving trends in VITAS Healthcare. Chemed announced a five-year $450 million amended and restated credit agreement. Roto-Rooter completed acquisitions for San Francisco and Fort Worth franchise territories. There have been recent insider selling activities. Chemed continued its share repurchase program and declared a quarterly dividend of $0.60 per share. The share price as of April 17, 2026, was $384.61, representing a decline of 31.76% from April 21, 2025.